The Financial Times has published today a very short review about the immunotherapy market. This business is currently dominated by Merck & Co and Bristol-Myers Squibb with blockbusters Keytruda and Opdivo, however these are already facing competition from Roche, Pfizer and AstraZeneca, which already have intensive immunotherapy development programs underway. According to EvaluatePharma, the sales volume of anti-PDL1 drugs, like Opdivo, was $10bn in 2017 and will reach $30bn by 2022, reaching $45bn in 2028. The revenues from the so-called CDK4 and CDK6 inhibitors–such as Pfizer’s Ibrance–will increase from $4bn to $10bn over the same period. The same investment made by large pharmaceutical groups in the immunotherapy business is unprecedented–the total number of ongoing clinical trials assessing the first three immunotherapies (Keytruda, Opdivo and Imfinzi) has increased from little less than 200 in 2015 to over 600. Moreover, there are new approaches to immunotherapy, some of which will be introduced at the impending American Association for Cancer Research congress in Chicago, where groups such as AstraZeneca will announce dozens of news.